Trial Outcomes & Findings for MetaNeb® Chest X-ray Study (NCT NCT02871258)
NCT ID: NCT02871258
Last Updated: 2024-09-24
Results Overview
Chest x-rays were scored using the Kelly scoring system to assess the presence of atelectasis on Day 2, after initiation of therapy with The MetaNeb® System. Scores for chest x-rays at Day 2 were compared to the scores for chest x-rays taken at baseline. 3 of the 8 subjects did not have measurable level of atelectasis at baseline and were excluded from the Kelly Score analyses. A score of 0 represents normal clear lungs whilst a score of 4 represent the whole lung is consolidated. A blinded reader scored each lung separately based on the Kelly Score scale. The Kelly scores from the left and right lung of each subject were averaged to get a mean score for each subject. Kelly Score ranges are as follows: 0 Normal; 1 Linear atelectasis; 1.25 a: one third of hemidiaphragm; 1.50b: two thirds of hemidiaphragm;1.75c: all of one hemidiaphragm; 2 Lobar consolidation; 3 Lobar collapse; 4 Bronchial consolidation (whole lung, bronchopneumonia etc.,)
COMPLETED
NA
8 participants
Approximately 48 hours post-initiation of therapy with The MetaNeb® System.
2024-09-24
Participant Flow
Participant milestones
| Measure |
The MetaNeb® System Treatment
Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment.
The MetaNeb® System
|
|---|---|
|
Overall Study
STARTED
|
8
|
|
Overall Study
COMPLETED
|
8
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
MetaNeb® Chest X-ray Study
Baseline characteristics by cohort
| Measure |
The MetaNeb® System Treatment
n=8 Participants
Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment.
The MetaNeb® System
|
|---|---|
|
Age, Continuous
|
69.6 Years
STANDARD_DEVIATION 5.90 • n=99 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
6 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
7 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
White
|
7 Participants
n=99 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
|
BMI
|
28.18 kg/m^2
STANDARD_DEVIATION 3.271 • n=99 Participants
|
|
History of Asthma
Yes
|
0 Participants
n=99 Participants
|
|
History of Asthma
No
|
8 Participants
n=99 Participants
|
|
COPD
Yes
|
2 Participants
n=99 Participants
|
|
COPD
No
|
6 Participants
n=99 Participants
|
|
Obstructive Sleep Apnea
Yes
|
0 Participants
n=99 Participants
|
|
Obstructive Sleep Apnea
No
|
8 Participants
n=99 Participants
|
|
Other Pulmonary Condition
Yes
|
1 Participants
n=99 Participants
|
|
Other Pulmonary Condition
No
|
7 Participants
n=99 Participants
|
|
Bronchiectasis
Yes
|
0 Participants
n=99 Participants
|
|
Bronchiectasis
No
|
8 Participants
n=99 Participants
|
|
Neuromuscular disease
Yes
|
0 Participants
n=99 Participants
|
|
Neuromuscular disease
No
|
8 Participants
n=99 Participants
|
|
Cystic Fibrosis
Yes
|
0 Participants
n=99 Participants
|
|
Cystic Fibrosis
No
|
8 Participants
n=99 Participants
|
PRIMARY outcome
Timeframe: Approximately 48 hours post-initiation of therapy with The MetaNeb® System.Chest x-rays were scored using the Kelly scoring system to assess the presence of atelectasis on Day 2, after initiation of therapy with The MetaNeb® System. Scores for chest x-rays at Day 2 were compared to the scores for chest x-rays taken at baseline. 3 of the 8 subjects did not have measurable level of atelectasis at baseline and were excluded from the Kelly Score analyses. A score of 0 represents normal clear lungs whilst a score of 4 represent the whole lung is consolidated. A blinded reader scored each lung separately based on the Kelly Score scale. The Kelly scores from the left and right lung of each subject were averaged to get a mean score for each subject. Kelly Score ranges are as follows: 0 Normal; 1 Linear atelectasis; 1.25 a: one third of hemidiaphragm; 1.50b: two thirds of hemidiaphragm;1.75c: all of one hemidiaphragm; 2 Lobar consolidation; 3 Lobar collapse; 4 Bronchial consolidation (whole lung, bronchopneumonia etc.,)
Outcome measures
| Measure |
The MetaNeb® System Treatment
n=5 Participants
Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment.
The MetaNeb® System
|
|---|---|
|
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 2 : Baseline Score
|
1.63 scores on a scale
Standard Deviation 0.18
|
|
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 2 : Day 2 Score
|
1.75 scores on a scale
Standard Deviation 0.35
|
|
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 4 : Baseline Score
|
1.25 scores on a scale
Standard Deviation 0.00
|
|
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 4 : Day 2 Score
|
1.13 scores on a scale
Standard Deviation 0.18
|
|
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 5 : Baseline Score
|
1.13 scores on a scale
Standard Deviation 0.18
|
|
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 5 : Day 2 Score
|
1.25 scores on a scale
Standard Deviation 0.0
|
|
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 6 : Baseline Score
|
0.75 scores on a scale
Standard Deviation 1.06
|
|
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 6 : Day 2 Score
|
1.25 scores on a scale
Standard Deviation 0.35
|
|
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 8 : Baseline Score
|
1.13 scores on a scale
Standard Deviation 0.18
|
|
Chest X-ray Score at Day 2 (Approximately 48 Hours) After Initiation of Therapy With The MetaNeb® System.
Subject 8 : Day 2 Score
|
0.63 scores on a scale
Standard Deviation 0.88
|
SECONDARY outcome
Timeframe: Approximately 24 hours and at Day 4, approximately 96 hours, or at discharge if discharge occurs before Day 4Mean chest x-ray score change for both lungs at Day 1 (approx. 24 hours) and at Day 4 (approx. 96 hours or at discharge, if discharge occurs before Day 4) after initiation of therapy with The MetaNeb® System. Scored using the Kelly score, as described above, to assess the presence of atelectasis. 3 of the 8 subjects did not have measurable level of atelectasis at baseline and were excluded from the Kelly Score analyses. A score of 0 represents normal clear lungs whilst a score 4 represent the whole lung is consolidated. A blinded reader scored each lung separately based on the Kelly Score scale. The Kelly scores from the left and right lung of each subject were averaged to get a mean score for each subject. Kelly Score ranges are as follows: 0 Normal; 1 Linear atelectasis; 1.25 a: one third of hemidiaphragm; 1.50b: two thirds of hemidiaphragm;1.75c: all of one hemidiaphragm; 2 Lobar consolidation; 3 Lobar collapse; 4 Bronchial consolidation (whole lung, bronchopneumonia etc.,)
Outcome measures
| Measure |
The MetaNeb® System Treatment
n=5 Participants
Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment.
The MetaNeb® System
|
|---|---|
|
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 2: Baseline Score
|
1.63 scores on a scale
Standard Deviation 0.18
|
|
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 2: Day 1 Score
|
1.75 scores on a scale
Standard Deviation 0.35
|
|
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 2: Day 4/Early Termination Score
|
1.25 scores on a scale
Standard Deviation 0.00
|
|
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 4: Baseline Score
|
1.25 scores on a scale
Standard Deviation 0.00
|
|
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 4: Day 1 Score
|
1.25 scores on a scale
Standard Deviation 0.00
|
|
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 4: Day 4/Early Termination Score
|
1.13 scores on a scale
Standard Deviation 0.18
|
|
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 5: Baseline Score
|
1.13 scores on a scale
Standard Deviation 0.18
|
|
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 5: Day 1 Score
|
1.13 scores on a scale
Standard Deviation 0.18
|
|
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 5: Day 4/Early Termination Score
|
1.13 scores on a scale
Standard Deviation 0.18
|
|
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 6: Baseline Score
|
0.75 scores on a scale
Standard Deviation 1.06
|
|
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 6: Day 1 Score
|
1.25 scores on a scale
Standard Deviation 0.35
|
|
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 6: Day 4/Early Termination Score
|
1.25 scores on a scale
Standard Deviation 0.35
|
|
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 8: Baseline Score
|
1.13 scores on a scale
Standard Deviation 0.18
|
|
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 8: Day 1 Score
|
1.13 scores on a scale
Standard Deviation 0.18
|
|
Chest X-ray Assessed by Kelly Atelectasis Score at Day 1 (Approximately 24 Hours) and Day 4 (Approximately 96 Hours, or at Discharge if Discharge Occurs Before Day 4), Compared to Baseline.
Subject 8: Day 4/Early Termination Score
|
0.63 scores on a scale
Standard Deviation 0.88
|
SECONDARY outcome
Timeframe: Comparing baseline, Day 1, Day 2, and Day 4/discharge.Chest x-ray improvement using a comparative scale after a minimum of forty-eight (48) hours of therapy with The MetaNeb® System. Chest x-ray improvement assessed using comparative scale for baseline, Day 1, Day 2, and Day 4/discharge. Four chest x-rays for each enrolled subject (baseline, Day 1, Day 2, and day 4/discharge), with date and time masked, were sent to the radiologist for comparison. The radiologist ranked the four x-rays as 1, 2, 3, or 4 (1 = least atelectasis, 4 = most atelectasis). \*Subjects 3 and 4 were discharged on Day 2, and therefore the Day 2 and Day 4/Early Discharge Chest X-rays are one in the same for the purposes of the analysis
Outcome measures
| Measure |
The MetaNeb® System Treatment
n=8 Participants
Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment.
The MetaNeb® System
|
|---|---|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 5 - Day 1
|
4 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 1 - Baseline
|
4 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 1 - Day 1
|
2 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 1 - Day 2
|
3 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 1 - Day 4/Early Discharge
|
1 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 2 - Baseline
|
3 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 2 - Day 1
|
4 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 2 - Day 2
|
2 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 2 - Day 4/Early Discharge
|
1 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 3 - Baseline
|
3 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 3 - Day 1
|
2 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 3 - Day 2*
|
1 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 3 - Day 4/Early Discharge*
|
1 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 4 - Baseline
|
2 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 4 - Day 1
|
1 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 4 - Day 2*
|
3 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 4 - Day 4/Early Discharge*
|
3 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 5 - Baseline
|
3 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 5 - Day 2
|
2 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 5 - Day 4/Early Discharge
|
1 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 6 - Baseline
|
4 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 6 - Day 1
|
3 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 6 - Day 2
|
2 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 6 - Day 4/Early Discharge
|
1 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 7 - Baseline
|
1 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 7 - Day 1
|
2 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 7 - Day 2
|
4 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 7 - Day 4/Early Discharge
|
3 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 8 - Baseline
|
4 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 8 - Day 1
|
3 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 8 - Day 2
|
2 scores on a scale
|
|
Chest X-ray Improvement Using a Comparative Scale (Comparing Baseline, Day 1, Day 2, and Day 4/Discharge).
Subject 8 - Day 4/Early Discharge
|
1 scores on a scale
|
SECONDARY outcome
Timeframe: Oxygenation Index (SpO2 /FiO2 ratio) at Baseline, Day 1 AM, Day 1 PM, Day 2 AM, Day 2 PM, and Day 4/early dischargeOxygenation Index (SpO2 /FiO2 ratio) at Day 1, Day 2, and day 4/discharge compared to baseline. SPO2/FiO2 is available for only the 6 subjects that received oxygen during the study. Subjects 3 and 4 did not receive oxygen and no SPO2/FiO2 ratios were calculated. higher SPO2/FiO2 value indicates better oxygenation.
Outcome measures
| Measure |
The MetaNeb® System Treatment
n=6 Participants
Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment.
The MetaNeb® System
|
|---|---|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 8 - Day 2 AM
|
NA SPO2/FiO2 ratio
Subject not on Oxygen.
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 1 - Baseline
|
267 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 1 - Day 1 AM
|
275 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 1 - Day 1 PM
|
275 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 1 - Day 2 AM
|
278 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 1 - Day 2 PM
|
313 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 1 - Day 4/Early Discharge
|
275 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 2 - Baseline
|
218 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 2 - Day 1 AM
|
291 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 2 - Day 1 PM
|
300 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 2 - Day 2 AM
|
NA SPO2/FiO2 ratio
Subject not on Oxygen.
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 2 - Day 2 PM
|
NA SPO2/FiO2 ratio
Subject not on Oxygen.
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 2 - Day 4/Early Discharge
|
NA SPO2/FiO2 ratio
Subject not on Oxygen.
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 5 - Baseline
|
350 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 5 - Day 1 AM
|
357 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 5 - Day 1 PM
|
336 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 5 - Day 2 AM
|
354 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 5 - Day 2 PM
|
336 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 5 - Day 4/Early Discharge
|
NA SPO2/FiO2 ratio
Subject not on Oxygen.
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 6 - Baseline
|
269 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 6 - Day 1 AM
|
NA SPO2/FiO2 ratio
Subject not on Oxygen.
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 6 - Day 1 PM
|
346 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 6 - Day 2 AM
|
NA SPO2/FiO2 ratio
Subject not on Oxygen.
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 6 - Day 2 PM
|
NA SPO2/FiO2 ratio
Subject not on Oxygen.
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 6 - Day 4/Early Discharge
|
NA SPO2/FiO2 ratio
Subject not on Oxygen.
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 7 - Baseline
|
309 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 7 - Day 1 AM
|
325 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 7 - Day 1 PM
|
400 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 7 - Day 2 AM
|
400 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 7 - Day 2 PM
|
NA SPO2/FiO2 ratio
Subject not on Oxygen.
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 7 - Day 4/Early Discharge
|
350 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 8 - Baseline
|
350 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 8 - Day 1 AM
|
357 SPO2/FiO2 ratio
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 8 - Day 1 PM
|
NA SPO2/FiO2 ratio
Subject not on Oxygen.
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 8 - Day 2 PM
|
NA SPO2/FiO2 ratio
Subject not on Oxygen.
|
|
Oxygenation Index (SpO2 /FiO2 Ratio).
Subject 8 - Day 4/Early Discharge
|
NA SPO2/FiO2 ratio
Subject not on Oxygen.
|
SECONDARY outcome
Timeframe: Patient reported level of dyspnea assessed by Modified Borg Dyspnea Scale on Baseline (Day 0), Day 1, and Day 2.Patient reported level of dyspnea (assessed by Modified Borg Dyspnea Scale).This is a scale that asks patients to rate the difficulty of their breathing. It starts at number zero (0) where the breathing is causing the patient no difficulty at all, and progresses through to number ten (10) where the patients' breathing difficulty is maximal. 0: Nothing at all; 0.5: Very, very slight (just noticeable); 1: Very slight; 2: Slight; 3: Moderate; 4: Somewhat severe; 5: Severe; 7: Very severe; 9: Very, very severe (almost maximal); 10: Maximal.
Outcome measures
| Measure |
The MetaNeb® System Treatment
n=8 Participants
Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment.
The MetaNeb® System
|
|---|---|
|
Patient Reported Level of Dyspnea Assessed by Modified Borg Dyspnea Scale.
Mean Score at Baseline
|
3.5 scores on a scale
Standard Deviation 1.31
|
|
Patient Reported Level of Dyspnea Assessed by Modified Borg Dyspnea Scale.
Mean Score at Day 1
|
3.25 scores on a scale
Standard Deviation 1.58
|
|
Patient Reported Level of Dyspnea Assessed by Modified Borg Dyspnea Scale.
Mean Score at Day 2
|
1.94 scores on a scale
Standard Deviation 1.15
|
SECONDARY outcome
Timeframe: Respiratory status evaluation at time of enrollment and on Day 2Change in patient respiratory status (Respiratory Status Evaluation). Physician observation and evaluation of patient respiratory status at time of enrollment (baseline) and on Day 2 to assess if worse, unchanged, or improved through: * Lung assessment: percussion * Lung assessment: Auscultation * Cough assessment * Secretion assessment * oxygenation * Work of breathing * Other observations: General appearance, mental acuity, respiratory pain
Outcome measures
| Measure |
The MetaNeb® System Treatment
n=8 Participants
Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment.
The MetaNeb® System
|
|---|---|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Secretion Assessment · Improved
|
6 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Secretion Assessment · Unchanged
|
2 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Lung Assessment: Percussion · Improved
|
7 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Lung Assessment: Percussion · Unchanged
|
1 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Lung Assessment: Percussion · Worse
|
0 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Lung Assessment: Auscultation · Improved
|
7 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Lung Assessment: Auscultation · Unchanged
|
1 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Lung Assessment: Auscultation · Worse
|
0 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Cough Assessment · Improved
|
7 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Cough Assessment · Unchanged
|
1 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Cough Assessment · Worse
|
0 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Secretion Assessment · Worse
|
0 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Oxygenation · Improved
|
6 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Oxygenation · Unchanged
|
2 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Oxygenation · Worse
|
0 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Work of Breathing · Improved
|
5 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Work of Breathing · Unchanged
|
3 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Work of Breathing · Worse
|
0 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Other Observations (General Appearance, Mental Acuity, Respiratory Pain) · Improved
|
7 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Other Observations (General Appearance, Mental Acuity, Respiratory Pain) · Unchanged
|
1 Participants
|
|
Change in Patient Respiratory Status Assessed by Subjective Physician Respiratory Status Evaluation.
Other Observations (General Appearance, Mental Acuity, Respiratory Pain) · Worse
|
0 Participants
|
Adverse Events
The MetaNeb® System Treatment
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Baxter Clinical Trials Disclosure Call Center
Baxter Healthcare
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place